Treatment with elagolix was associated with sustained reduction in average monthly dysmenorrhea and non-menstrual pelvic pain through a 12-month treatment period.
A flexible extended regimen of 20 mg ethinylestradiol and 3 mg drospirenone (FlexibleMIB) was shown to be superior to placebo for reducing endometriosis-related pain.
At 3 months, significantly more women receiving both doses of elagolix had reductions in dysmenorrhea and nonmenstrual pelvic pain compared with those receiving placebo.
Women with chronic pelvic pain had greater connectivity in "pain" regions of the brain, regardless of presence of endometriosis.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis